Brought to you by 
Immatics US launches with $40mm Series A investment from parent Immatics Biotechnologies
15 Sep 2017
Executive Summary
Cancer immunotherapies developer Immatics Biotechnologies GMBH and the University of Texas MD Anderson Cancer Center together launched Immatics US Inc., a new adoptive cellular therapeutics (ACT) subsidiary of Immatics Biotechnologies. The new division received $40mm in Series A funding from its parent; MD Anderson is also a shareholder.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immatics US launches with $40mm Series A investment from parent Immatics Biotechnologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice